Загрузка...
Experience with sunitinib in the treatment of metastatic renal cell carcinoma
Following approval of the oral, multitargeted tyrosine kinase inhibitor sunitinib malate for the treatment of patients with metastatic renal cell carcinoma (mRCC) in Europe and the USA in 2006, the agent has had a substantial impact on the treatment landscape in this setting. Sunitinib is now recomm...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3441135/ https://ncbi.nlm.nih.gov/pubmed/23024706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287212454933 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|